Life Science Investing Leading Independent Proxy Advisory Firm ISS Recommends STAAR Stockholders Vote "FOR" Alcon Merger
Life Science Investing Broadwood Partners: Leading Proxy Advisory Firm Glass Lewis Reaffirms Recommendation "AGAINST" STAAR Surgical Sale to Alcon
Life Science Investing Broadwood Partners Comments on STAAR Surgical Board Dissent on the Revised Sale to Alcon
Life Science Investing Yunqi Capital Comments on STAAR Surgical's Go-Shop Process and Alcon's Revised Offer
Life Science Investing Broadwood Partners Responds to Alcon's Increase to Proposed Acquisition Price of STAAR Surgical
Life Science Investing Broadwood Partners: Proxy Advisory Firm Egan-Jones Reaffirms Its Recommendation STAAR Surgical Shareholders Vote "AGAINST" Sale to Alcon
Life Science Investing Broadwood Partners Working to Call Special Meeting of STAAR Surgical Shareholders to Remove Three Directors
Life Science Investing Broadwood Partners Calls for the Appointment of New Directors at STAAR Surgical to Oversee Go-Shop Process
Life Science Investing Yunqi Capital Applauds STAAR Surgical's Strong Third Quarter Results and Reiterates That the Proposed Sale to Alcon Should Be Terminated
Life Science Investing Broadwood Partners Condemns Alcon's Fallacious Attacks on STAAR Surgical and Its Prospects
Life Science Investing Yunqi Capital Issues Letter to STAAR Surgical Board Calling for Termination of the Proposed Merger with Alcon
